

Our Founding Background
Our founder, Tasuku Okamoto, was engaged in R&D of pharmaceuticals and medical devices in the new business development department of a large company, later becoming an independent entrepreneur involved in the management of a bio-venture company for about 15 years. There, he experienced business successes and failures, including clinical studies for drug discovery and the development of luminescence-molecular imaging of intracellular signal transduction, anti-cancer peptide vaccines, and organ-on-a-chip drug discovery technology. At the same time, he has witnessed the proliferation of biopharmaceuticals and the emergence of new technologies, such as the practical application of genetic screening in cancer care and regenerative medicine.
In this context, he has also faced many medical challenges: 1) the still low chance for patients to encounter the molecularly-targeted drugs they seek in cancer genome medicine, 2) the practical application of regenerative medicine with high developmental hurdles, and 3) the fact that many patients are facing rare diseases for which there is still no known cure.
Now we have successfully developed a technology that can provide a new modality called cell therapy. We are ready to embark once again on the quest for personalized medicine that will allow patients to choose the treatment that best suits their individual needs.



Company Profile
Company Name | Opticell, Inc. |
Establishment | June 23, 2023 |
Company President | Tasuku Okamoto |
Share Capital | 5,500,000 Japanese yen |
Headquarters | Cross Gate 7th Floor, 1-101-1 Sakuragi-cho Naka-ku, Yokohama, Kanagawa, Japan 231-0062. |
Laboratory 1 | Shonan iPark Laboratory: Open Laboratory in Shonan Health Innovation Park, 2-26-1 Muraoka Higashi, Fujisawa-shi, Kanagawa, 251-8555 Japan |
Laboratory 2 | GeneCare Research Institute Co.,Ltd. Share Laboratory 116-1 Tokiwa, Kamakura, Kanagawa, 248-0022 Japan |
Origin of Company Name | “Opticell” was born as a unification of the words “optimize” and “cell” to capture the essence of our goals: the best and most efficient utilization of cells. |
Founder Message
At Opticell, Inc., our philosophy is to contribute to the advancement of personalized medicine. Through the development of cellular medicine technology, which is expected to be the next generation of medicine, we strive to advance personalized medicine that would allow patients to choose the best treatment for their individual needs.
For example, in the future, we envision the spread of personal cell medicine. In this approach, patients' skin cells are used to create hematopoietic stem cells and neural stem cells. These cells can treat blood and immune disorders and neurological dysfunctions.
In the area of cancer treatment, the development of cancer immuno-cell medicine will be focused on, and the development of immuno-cell medicine that attacks cancer cells by generating T cells from the patient's own skin cells will be challenged.
This time, we have developed a technology that provides a new therapeutic modality: direct cell reprogramming of somatic cells (transdifferentiation), which uses our proprietary peptide technology.
We are now ready to begin realizing personalized medicine, which allows patients to choose the best treatment for their needs.
We look forward to the continued support and cooperation of our stakeholders.

CEO and Founder
Tasuku Okamoto
Career
1984 | Graduate School of Environmental Science, University of Tsukuba (Master’s Degree) |
2007 | Graduate School of Business Management System Science, University of Tsukuba (MBA) |
1984~2007 | Engaged in R&D and clinical development in the pharmaceutical and medical device business division of Toray Industries, Inc. |
2007 | President of ProbeX, a biopharmaceutical start-up engaged in drug discovery R&D using optical molecular imaging technologies. |
2013 | Founded CREO Bioscience Inc. and worked on organ-on-a-chip drug discovery |
2023 | Founded OptiCell Inc. |
Access
Headquarters
Cross Gate 7th Floor, 1-101-1 Sakuragi-cho Naka-ku, Yokohama, Kanagawa, Japan 231-0062
URL https://opticell.co.jp/
Research laboratory
116-1 Tokiwa, Kamakura, Kanagawa, Japan 248-0022
Shared lab facility in GeneCare Research Institute Co., Ltd.